AcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint

AcelRx Pharmaceuticals Inc ACRX disclosed top line results of its ARX-04 final stage study, which met its primary endpoint.

The specialty pharmaceutical company indicated 76 adults were given the treatment with ARX-04 in this trial that witnessed a mean pain intensity difference to baseline (PID) of 2.9 from a baseline of 8.1, or 35 percent, on a 0 – 10 numeric rating scale at 60 minutes. In short, the trial demonstrated reduced pain intensity in ER patients.

Following the news, the stock traded up by $0.39, or 10.46 percent, to $4.12 in the pre-market on Monday.

Related Link: Importance Of Phase III Trials

AccelRx said ARX-04 illustrated a predicted commencement of activity in patients enrolled in SAP302. The company pointed out that patients reported a mean pain intensity fall of 1.1 compared to baseline 15 minutes after the first administration of ARX-04, and a drop of 1.9 following an half-an-hour of the administration of the drug candidate.

The company's co-founder and chief medical officer, Pamela Palmer, said, "In addition to putting combat units in danger, drug-induced cognitive effects can impede diagnosis and treatment in a civilian emergency room. If borne out, ARX-04's onset of pain relief, sublingual dosage form and side effect profile could make it an attractive option for doctors considering opioid analgesic treatment in emergency rooms and field-based settings."